Saint Cloud, Minn. - Microbiologics has announced an additional 650 square foot Biosafety Level 3 (BSL-3) facility within its existing building at the company’s global headquarters in St. Cloud, Minnesota. This addition comes just 9 months after announcing the completion of their first BSL-3 laboratory at the company’s San Diego, California facility in August 2020. The additional BSL-3 facility allows for increased capabilities and capacity for Microbiologics to provide anti-infective testing, assay development and biomaterial production services for highly infectious pathogens, including COVID-19 and other emerging diseases.

Microbiologics is a leading contract research and manufacturing organization (CRMO), partnering with pharmaceutical and diagnostic companies to bring new lifesaving technology, anti-infective drugs, vaccines and therapeutics to market. Brad Goskowicz, Microbiologics Chief Executive Officer, commented, "Demanding timelines and complex regulatory requirements are prompting pharmaceutical and diagnostic companies to outsource aspects of their R&D and QC functions to a qualified CRMO partner. We’re able to provide end-to-end, highly-collaborative support where and when our clients need it, which enables them bring new products to market rapidly and safely."

Providing a full menu of antiviral testing and assay development services, Microbiologics supports drug, vaccine and medical device development processes from discovery through post-market surveillance. Examples of these specialized assay services include virus neutralization, hemagglutination, immunoassay development within ELISA platforms and Single Radial Immunodiffusion (SRID) assays. Microbiologics is currently transferring a SARS-CoV-2 virus neutralization assay for the United States Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, acquired under the Department of Defense’s Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) contract number W911QY-21-C-0012. The company has responded to the COVID-19 global crisis by providing SARS-CoV-2 IVD controls and biomaterials for the development and validation of assays, vaccines, and therapies, as well as providing post-market surveillance testing of COVID-19 vaccines.

Microbiologics has a history deeply rooted in the biological controls industry with highly customizable and scalable manufacturing capabilities and an expansive distribution network. They have extensive expertise in the growth, titration, purification and production of viruses and microbes in a variety of formats for research, development and quality control applications. High-titer, highly purified, and inactivated intact virus, as well as synthetic nucleic acid and viral DNA and RNA are examples of the materials they regularly produce for clients. The company also has a repository of more than 10,000 viral stocks and clinical isolates used for screening antiviral and antimicrobial compounds.

When speaking about the new BSL-3 laboratories, which began construction in February 2021, Goskowicz stated, "Expanding our BSL-3 capacity allows us to continue co-creating and pursuing new ideas alongside our partners without limitation." He added, "At the heart of everything we do is an uncompromising commitment to supporting our partners on the frontlines and creating confidence is science. We care deeply about our clients’ needs and understand the impact their products will have on the lives of people throughout the world. It’s what drives us to continuously push ourselves to find better answers, better solutions, and better ways to serve."

About Microbiologics: Microbiologics is the foremost biological products and services provider, focused on protecting the health and safety of people around the world. For over 50 years, they have been partnering with healthcare and life science laboratories, manufacturers and suppliers across the globe to co-create and provide biological control materials, assay services and consulting for microbiology, molecular diagnostics and virology. Headquartered in Saint Cloud, Minnesota, the company has additional facilities in Michigan, Kentucky and California. Microbiologics has advanced industry standards for biological controls by adopting the most rigorous testing and quality standards including ISO 13485, ISO/IEC 17025, and ISO 17034. The company has an extensive distribution network spanning over 150 countries. For more information, visit Microbiologics, Inc.